98%
921
2 minutes
20
Background And Objectives: Safe and effective management of cancer-related pain is a worldwide challenge. In the search for treatment options, natural products used in Chinese herbal medicines (CHMs) have received attention in clinical studies for their effects on cancer-related pain. The objective of this systematic review is to evaluate the clinical evidence for topically applied CHMs as adjunctive treatments for cancer pain management.
Methods: Nine biomedical databases and 4 clinical trial registries were searched for randomized-controlled trials (RCTs) that reported measures of pain and/or quality of life. Risk of bias was assessed using the Cochrane tool. Meta-analysis employed mean difference (MD) with 95% confidence intervals (random effects).
Results: Twenty (20) RCTs (1636 participants) met the inclusion criteria. Meta-analyses were grouped based on the comparisons and outcome measures. For pain intensity, there was a greater reduction in the topical CHM group versus placebo (MD -0.72 [-1.04, -0.40]), no difference when compared to tramadol (MD -0.15 [-0.38, 0.08]), and a greater reduction when topical CHMs were combined with conventional analgesic medications (MD -0.67 [-0.93, -0.40]). Analgesic onset time was reduced in the CHM group compared to tramadol (MD -26.02 [-27.57, -24.47] minutes), and for CHMs combined with conventional medications (MD -19.17 [-21.83, -16.52] minutes). When CHMs were combined with analgesic medications, improvements were found for duration of analgesia (MD 1.65 [0.78, 2.51] hours), analgesic maintenance dose (MD -31.72 [-50.43, -13.01] milligrams/day), and quality of life.
Conclusion: Addition of topical CHMs to conventional analgesic medications was associated with improved outcomes for pain intensity, some other pain-related outcomes, and measures of quality of life. Limitations included methodological issues in some studies and considerable heterogeneity in some pooled results.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10647965 | PMC |
http://dx.doi.org/10.1177/15347354231210870 | DOI Listing |
Diabetes Metab Syndr Obes
August 2025
Department of Endocrinology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, 450000, People's Republic of China.
Background: Chinese herbal medicines (CHMs) are used for type 2 diabetes mellitus combined with stable angina pectoris (T2DM-SAP), but their long-term effects lack real-world evidence.
Objective: To evaluate the effects of additional CHMs on angina readmission rates compared to standard treatment alone in patients with T2DM-SAP.
Methods: This retrospective cohort study included 704 patients with T2DM-SAP.
J Chromatogr A
October 2025
College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, China. Electronic address:
A reliable quality control system is crucial to ensure the quality consistency, clinical efficacy, and safety of Chinese herbal medicines (CHMs) and their preparations. Herein, high performance liquid chromatography (HPLC) five-wavelength fusion fingerprint (FWFFP) and its ratio quantitative fingerprint (ROFP) were established, with the innovative ratio systematically quantitative fingerprint method (RSQFM) applied for quality assessment. The 22 batches of Siegesbeckiae Herbas (SHs) were classified into six Grades (0.
View Article and Find Full Text PDFCan Commun Dis Rep
July 2025
Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, ON.
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are sexually transmitted and blood-borne infections that Canada is committed to eliminate as public health concerns. Accurate epidemiological estimates require cross-sectional data as input. The objective of this study was to estimate the prevalence of present HBV infection (hepatitis B surface antigen-positive) and proportion aware of their infection, the vaccine-induced HBV immunity, the prevalence of HCV antibodies (anti-HCV-positive), the prevalence of present HCV infection (RNA-positive) and proportion aware of their infection, in the household population in Canada.
View Article and Find Full Text PDFAnn Med
December 2025
Center of Cerebrovascular Diseases, Department of Neurology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Objective: To study the association between cerebral small vessel diseases (CSVD) and unfavorable hematoma morphology in primary intracerebral hemorrhage (ICH).
Methods: Patients with primary ICH who were admitted to West China Hospital of Sichuan University from March 2012 to January 2021 were consecutively included. The unfavorable hematoma morphology included any hypodensity, any irregularity, black hole, blend sign, Barras shape score ≥3, Barras density score ≥3, immature hematoma and combined Barras total score (CBTS) ≥4.
Adv Sci (Weinh)
August 2025
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and National Center for Nanoscience and Technology of China, Beijing, 100190, China.
Over centuries of clinical practice, Chinese herbal medicines (CHMs) have gained widespread recognition for their efficacy in treating various diseases. However, their complex material basis and relatively mild therapeutic efficacy limit their modernization and quality control. Recently, the application of pharmaceutical nanotechnology to CHMs has not only enhanced their efficacy, but also helped elucidate their material basis, thereby substantially advancing their modernization.
View Article and Find Full Text PDF